Sanofi scouts India for consumer buys; Lilly lobbies against new U.K. pricing;

@FiercePharma: Cut drug prices? Deloitte counts the ways. Story | Follow @FiercePharma 

> French drug maker Sanofi-Aventis, which has identified consumer healthcare as a key area of growth in India, is scouting for brand and business acquisitions in the local market. Report

> The U.K. government's planned introduction of a value-based pricing system could increase costs and bureaucracy for the industry, Eli Lilly told government officials. Article

> Richmond, VA, drugmaker Insmed said it has merged with Transave, a New Jersey-based bio-pharmaceutical company. Item

> Prescriptions for hormone replacement therapy have fallen more than 50 percent in the U.S. since 2001, but doctors are still inexplicably giving women high-dose pills linked to strokes and cancer, researchers reported. Report

> Experts warned on Friday that treating dengue, a potentially fatal disease caused by a mosquito-borne virus, will become more difficult in the future as more people around the world become overweight and obese. Story

> Sequenom is down more than 4.5 percent in early morning trading, to a recent $6.50, as company said it was pricing 14 million shares of its stock at $6 a share. Article

> Takeda has moved further into the vaccines business with the finalisation of a deal with Baxter International for the use of the U.S. firm's cell culture technology for the manufacture of a pandemic flu vaccine. Article

> A move by hedge fund Ramius to nominate three members to SurModics' board signals a likely proxy battle to control the struggling medical equipment maker, and the eventual sale of its pharma business or even the whole company. Report

Biotech News

 @FierceBiotech: Merck to buy SmartCells in $500M deal. News | Follow @FierceBiotech

 @JohnCFierce: After glancing over the OREX notes, I didn't see anything that hasn't been discussed before. Clear safety issues=big deal for developers. Follow @JohnCFierce

> Panel back's AZ's ($AZN) thyroid cancer drug vandetanib. Story

> Orexigen ($OREX) readies for expert panel review of Contrave. Article

> Microbix announces new flu vax subsidiary. Item 

And Finally... The Japanese government Friday confirmed the country's first outbreak of a high-risk bird flu in three years, though it stressed that there was no evidence the disease had spread beyond chickens. News

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.